Nichole Miller
Pulmonary Disease · Sylvania, OHNPI 1679991970
Payments from drug & device makers
Across 135 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$326
- GSK$296
- United Therapeutics Corporation$192
- Actelion Pharmaceuticals US, Inc.$181
- Harmony Biosciences LLC$176
- Mylan Specialty L.p.$156
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,64697%
- Education$793%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $326 |
| GSK | 17 | $296 |
| United Therapeutics Corporation | 12 | $192 |
| Actelion Pharmaceuticals US, Inc. | 7 | $181 |
| Harmony Biosciences LLC | 7 | $176 |
| Mylan Specialty L.p. | 8 | $156 |
| Baxter Healthcare | 4 | $139 |
| Boehringer Ingelheim | 7 | $137 |
| Grifols USA, LLC | 6 | $121 |
| Merck | 5 | $106 |
| Sanofi | 4 | $92 |
| Astellas Pharma US Inc | 1 | $79 |
| Insmed, Inc. | 4 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $66 |
| Phadia US Inc. | 3 | $65 |
| Regeneron Healthcare Solutions, Inc. | 3 | $62 |
| Bayer | 3 | $56 |
| Mallinckrodt Hospital Products Inc. | 2 | $50 |
| Amgen | 3 | $49 |
| Philips North America LLC | 3 | $46 |
| La Jolla Pharmaceutical Company | 3 | $43 |
| Shionogi Inc | 2 | $37 |
| Advanced Respiratory, Inc | 2 | $29 |
| Covis Pharma GmbH | 2 | $26 |
| Viatris Specialty LLC | 1 | $25 |
| Pfizer | 1 | $21 |
| Verona Pharma, Inc. | 1 | $20 |
| Medivance, Inc. | 1 | $20 |
| Pulmonx Corporation | 1 | $14 |
| Electromed, Inc. | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
How this compares
$2,725 in reported general payments places this provider in the 50th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 135 | $101,298 |
| Incruse ElliptaUmeclidinium Bromide | 86 | $37,421 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $24,497 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $19,185 |
| Advair HfaFluticasone Propion/Salmeterol | 44 | $17,038 |
| Spiriva HandihalerTiotropium Bromide | 13 | $8,503 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 46 | $8,012 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 13 | $7,112 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $7,030 |
| Arnuity ElliptaFluticasone Furoate | 24 | $6,603 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 189 | $5,220 |
| Fluticasone Propionate HfaFluticasone Propionate | 19 | $4,440 |
| Qvar RedihalerBeclomethasone Dipropionate | 12 | $3,525 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $2,947 |
| Roflumilast | 12 | $2,771 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Arnuity Ellipta | $296 | $164,508284 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere | $326 | $31,60952 claims |
| Boehringer IngelheimStiolto Respimat | $137 | $7,03013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Sylvania
- Bruce CorserCincinnati$8.2M
- Edward CordascoColumbus$8M
- Kristin HighlandCleveland$3.2M
- Brian ZenoColumbus$2.9M
- Jean ElwingCincinnati$2.4M
- Roy St JohnColumbus$1.9M
- Nishant GuptaCincinnati$1.5M
- Robert BaughmanCincinnati$1.1M
- Francis McCormackCincinnati$1.1M
- Leslie TolleCleveland$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.